Pneumococcal

Oritavancin (Orbactiv) is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.

Vaxneuvance was approved for an expanded indication by the FDA on June 22, 2022, for active immunization in children 6 weeks of age and older.

Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.

New recommendations provide some harmonization to make it easier for clinicians to lower the barriers to assessing and identifying eligible patients for the pneumococcal vaccine.

Expert emphasizes that it is important to acknowledge the critical role of pharmacists in overcoming barriers to vaccinations.

Ciprodex is approved for the treatment of ear infections, acute otitis media, and acute otitis externa.

Voriconazole (Vfend) is an azole antifungal indicated for the treatment of invasive aspergillosis and Candidemia in non-neutropenics and other deep tissue Candida infections.

Any antibiotic use was associated with higher rates of IBD, and the risk went up substantially with each course.

Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Even before the COVID-19 pandemic, vaccine hesitancy has been a challenge among adult patient populations.

V116 is a novel 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia.

Genome sequencing shows the clonality of outbreak isolates within each of 6 classes, which confirmed that recent transmissions accounted for high carriage.

Vaxneuvance was previously granted FDA Priority Review and Breakthrough Therapy designation for the prevention of invasive pneumococcal disease.

Electronic, open loop, clinical decision support system helped to produce a 38% lower overall mortality rate among patients with pneumonia.

The global impact of GBS causes approximately 150,000 deaths of babies each year.

The proof-of-concept study is expected to announce topline safety, tolerability, and immunogenicity results by the end of 2022.

Study shows there is no association between strep throat infection and the development of tics in children with a parent or sibling with a chronic tic disorder.

How would you respond to these patient questions?

Group B strep can cause dangerous infections in adults with certain chronic medical conditions.

The analysis of 204 countries and territories reveals that AMR is now a leading cause of death worldwide, which is higher than HIV/AIDS or malaria.

One viral protein could provide information to deter pneumonia causing the body’s exaggerated inflammatory response, new study results show.

The findings could help clinicians tailor the use of early antibiotics in newborns because only infants deemed at risk for infection should receive antibiotics.

Responses elicited by the pneumococcal vaccine for all 20 serotypes were similar whether administered with the COVID-19 vaccine or with placebo.

Lefamulin (Xenleta, Nabriva Therapeutics) is approved for the treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms.

The research team looked at a pooled analysis of all published studies to re-evaluate the relationship between regular exercise and the risk of developing pneumonia.

Chronic hypersensitivity pneumonitis is a long-term lung condition in which the interstitial tissue surrounding the alveoli of the lungs becomes inflamed and develops fibrosis.

Serotypes 22F, 33F, and 3 represent more than a quarter of invasive pneumococcal disease in children under the age of 5

Multiple GBS vaccine candidates are in development, but none are available despite development efforts spanning multiple decades.

AzaSite is indicated for the treatment of bacterial conjunctivitis caused by CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae.

It was previously known that beta-lactam antibiotics function by restricting cell wall growth, but the exact mechanics have remained unknown until now.